They conjugated iron-carrying CPNPs with the endothelin 3 (EDN3-CPNP), which specifically targets the melanoma endothelin-B receptor (EDNRB), and showed enhanced melanoma tumor targeting and tumor cell killing effects (Jasim and Gesquiere, 2019). Here, EDN3 is linked to neoplasm.